Comparison
Pramlintid vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
151126-32-8
2023788-19-2
Molecular weight
3949.4 g/mol
4813 g/mol
Half-life
no data
116 h
Sequence
no data
YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
4
of which in humans
0
4
Effects recorded
2
4
Open conflicts
1
1
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Pramlintid and Tirzepatide?
- Pramlintid is classified as "Metabolic", while Tirzepatide is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pramlintid or Tirzepatide?
- The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pramlintid and Tirzepatide in Germany and the United States?
- Germany: Pramlintid — Unapproved, Tirzepatide — Prescription. United States: Pramlintid — Prescription, Tirzepatide — Prescription. These are factual summaries with source and review date on the individual pages.